

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CK Life Sciences Int'l. (Holdings) Inc.

長江生命科技集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 0775)

**VOLUNTARY ANNOUNCEMENT RELATING TO
LICENSING AGREEMENT TO DISTRIBUTE A DIAGNOSTIC OPTION TO
ADDRESS COVID-19 TESTING NEEDS IN HONG KONG
AND
RESUMPTION OF TRADING**

The board of directors of CK Life Sciences Int'l., (Holdings) Inc. (the “**Company**”) announces that CK Life Sciences Development Limited (a wholly-owned subsidiary of the Company) entered into a licensing agreement with a subsidiary of Singapore’s Agency for Science, Technology and Research (“**A*Star**”) to make, distribute, market and sell a SARS-CoV-2 RT-PCR diagnostic test kit for COVID-19 detection in Hong Kong and worldwide.

The diagnostic test kit is designed to detect the presence of the SARS-CoV-2 viral RNA specifically. The kit delivers a high level of sensitivity and accuracy and does not show any cross reactivity with other closely-related respiratory viruses including SARS-CoV, MERS-CoV and influenza.

Co-developed by A*Star and Tan Tock Seng Hospital, the kit has been given Provisional Authorisation from the Health Sciences Authority, Singapore, for its intended use in Singapore. Since February 2020, the kit has been implemented in six local public hospitals and one private hospital group in Singapore.

The Company believes that the kit is a timely option to help expedite the testing of the increasing number of suspected COVID-19 cases in Hong Kong. The kit is already in use in Singapore hospitals and is a proven technology that is immediately applicable and results can be available within 2 to 4 hours. It would also enable more healthcare institutions and laboratories to perform testing, thereby facilitating prompt isolation and treatment of patients.

An application has been made by the Company to the Stock Exchange for the resumption of trading in the Company's shares with effect from 9:00 a.m. on 30 March 2020.

By Order of the Board
CK Life Sciences Int'l., (Holdings) Inc.
Eirene Yeung
Company Secretary

Hong Kong, 27 March 2020

As at the date of this announcement, the Executive Directors of the Company are Mr. Li Tzar Kuoi, Victor (Chairman), Mr. Kam Hing Lam, Mr. Ip Tak Chuen, Edmond, Mr. Yu Ying Choi, Alan Abel and Dr. Toh Kean Meng, Melvin; and the Non-executive Directors are Mr. Peter Peace Tulloch, Mrs. Kwok Eva Lee (Independent Non-executive Director), Mr. Colin Stevens Russel (Independent Non-executive Director), Mr. Kwan Kai Cheong (Independent Non-executive Director) and Mr. Paul Joseph Tighe (Independent Non-executive Director).